- Conditions
- Eye-tracking
- Interventions
- EYE-SYNC eye-tracking, SCAT-3 subtests, DEM, Simple Reaction Time subtest of ANAM-SRT, Level of Alertnesss
- Device · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Santa Barbara, California • Corvallis, Oregon + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
- Interventions
- MRTX1133
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
- Conditions
- Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent, Endometroid Ovarian Carcinoma, Clear Cell Ovarian Carcinoma
- Interventions
- Cytokine-Induced Memory-like Natural Killer Cells, Interleukin 2
- Biological · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Breast Tumors, Cancer of Breast, Cancer of the Breast, Malignant Neoplasm of Breast
- Interventions
- Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy Male Volunteers
- Interventions
- Oral [14C] PF-07799544, Oral Unlabeled PF-07799544, IV [14C] PF-07799544
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer's Disease
- Interventions
- GC021109, Placebo
- Drug · Other
- Lead sponsor
- GliaCure, Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 5
- States / cities
- Long Beach, California • Deerfield Beach, Florida • Hallandale, Florida + 2 more
- Conditions
- Scoliosis
- Interventions
- 3D topographical scan
- Diagnostic Test
- Lead sponsor
- NSite Medical
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Durham, North Carolina
- Conditions
- HIV Infections
- Interventions
- BMS-955176
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Pelvic Organ Prolapse
- Interventions
- Robotic-assisted laparoscopic sacrocolpopexy, Open sacrocolpopexy
- Procedure
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Health
- Interventions
- Dinalbuphine sebacate, Nalbuphine HCl
- Drug
- Lead sponsor
- Lumosa Therapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Parkinson Disease
- Interventions
- Digital Speech Application
- Device
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pre-eclampsia
- Interventions
- Placebo, RLX030
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Mobile, Alabama • Lexington, Kentucky • Louisville, Kentucky + 1 more
- Conditions
- Breast Cancer
- Interventions
- Poziotinib
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Bermekimab Monoclonal Antibody 400 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Single-ventricle, Stenosis
- Interventions
- Cardiopulmonary Exercise Testing (CPET), Shear Wave Elastography Scan
- Diagnostic Test
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 20 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Magnetic Resonance Imaging
- Interventions
- ImageReady MR Conditional Defibrillation System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Jonesboro, Arkansas • Pasadena, California + 31 more
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia 3
- Interventions
- Not listed
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care)
- Drug · Radiation · Procedure
- Lead sponsor
- Sue Yom
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Graft-Versus-Host Disease (GVHD) Acute on Chronic
- Interventions
- Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma
- Interventions
- Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
- Interventions
- LP-184, Olaparib, Nivolumab & Ipilimumab
- Drug
- Lead sponsor
- Lantern Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more
- Conditions
- Bronchopulmonary Dysplasia (BPD)
- Interventions
- Metformin (open-label)
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 7 Days to 6 Months
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 59
- States / cities
- Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
- Conditions
- Muscle Weakness
- Interventions
- Magnetic Muscle Stimulation (MMS) device
- Device
- Lead sponsor
- Zeltiq Aesthetics
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Pleasanton, California • Sacramento, California